Barron's Medical Journal Reporting From Baylor College Of Medicine, Houston Medical Center, Houston, Texas
President Obama, Governor Rick Perry and President of MD Anderson Ronald DePinho, M.D. Medical Teams To Meet Next Year.
Houston ( AP )Barron's Medical Journal has called for a meeting between President Obama, Governor Rick Perry and President of MD Anderson Ronald DePinho, M.D. Medical Teams. The Objective is to put together a road map that will allow new born babies born Today to live 22 percent longer. President Obama Health Care Reform Act, Rick Perry commitment to Stem Cell Research,
And Ronald DePinho & Jim Allison Chief of Immunology at MD Anderson vision and proven 24% success
rate with immune research. Together it is clear, Genomic Science and the protein to allow your immune system to stop the advancement of Breast Cancer Tumors is the cure for Breast Cancer.
Brought To You By Antiques of River Oaks Houston,Tx
Jim Allison’s discoveries led to the first drug ever to improve the survival rate of patients with metastatic melanoma – by itself a remarkable achievement. His insights into the basic biology of immune system T cells will be broadly applicable to a
variety of cancers and his gifted scientific leadership is essential to the definitive progress that must be made against these diseases,” said MD Anderson President Ronald DePinho, M.D.
“We’re delighted that he will lead our collaborative immunotherapy initiative to continue unleashing the power of the immune system against cancer,” DePinho said. “Dr. Allison embodies an important principle for us. It’s not just about doing elegant science, although that’s certainly the case here. It doesn’t count unless it has a meaningful impact on the well-being of our patients. That’s the bottom line.”
Accelerating transition of drug combinations to clinic
“The main reason for coming to MD Anderson is the opportunity offered by a clinical community that’s open to using immunological approaches to treat cancer combined with other therapies,” Allison said.
“We plan to build a large platform where basic scientists interested in mouse models of cancer work side-by-side with physician-scientists who treat patients to analyze tissues from those patients and truly understand the mechanisms involved,” Allison said. “We can accelerate the transition of new combinations of drugs into the clinic beyond phase I clinical trials and broaden our focus beyond melanoma and prostate cancer to other types of cancer.
“We all know that no single drug will cure cancer. I think this is where we’ll start getting cures, or at least long-term survival of patients. There’s lots of enthusiasm for this approach at MD Anderson and I’m really excited about it,” he said.
Allison will play an instrumental role in MD Anderson’s recently announced Moon Shots Program to dramatically accelerate the pace of converting scientific discoveries into clinical advances that reduce cancer deaths.
He is a member of the National Academy of Sciences and the Institute of Medicine, as well as a fellow of the American Academy of Microbiology and the American Association for the Advancement of Science. He also is an investigator of the Howard Hughes Medical Institute.
Allison was chair of the immunology program and director of the Ludwig Center for
Cancer Immunotherapy at Memorial Sloan-Kettering Cancer Center in New York.He started at MD Anderson on Nov. 1.
Immune system personalizes therapy
Rather than attacking cancer cells directly, the drug developed from Allison’s research makes those cells “visible” to the immune system by blocking a molecule he discovered that inhibits immune response.
About 25 percent of patients with late stage metastatic melanoma who took ipilimumab in clinical trials have lived for five years or longer. The drug, known commercially as Yervoy, was approved by the U.S. Food and Drug Administration in May 2011.
Governor Rick Perry Texas' top ranking in the creation of biotech jobs, another sign that the Lone Star State is the place where high-tech visionaries of all types are planting their flags. However, very few of these fields are more promising, or important, than this one. Adult stem cell research can change the world through regenerative medicine and its untapped potential to tackle some of the most challenging diseases known to man.
GenNXeix Biotech Analytics Research has shown genomics, pluripotent stem (iPS) cells is the Future for Treating Breast Cancer along with Bacteria process called quorum sensing. Pluripotency (from the Latin plurimus, meaning very many, and potens, meaning having power) refers to a stem cell that has the potential to differentiate into any of the three germ layers: endoderm (interior stomach lining, gastrointestinal tract, the lungs), mesoderm (muscle, bone, blood, urogenital), or ectoderm (epidermal tissues and nervous system). Bacteria communicate with one another using chemical signal molecules. As in higher organisms, the information supplied by these molecules is critical for synchronizing the activities of large groups of cells. In bacteria, chemical communication involves producing, releasing, detecting, and responding to small hormone-like molecules termed auto inducers. This process, termed quorum sensing, allows bacteria to monitor the environment for other bacteria and to alter behavior on a population-wide scale in response to changes in the number and/or species present in a community. Most quorumsensing-controlled processes are unproductive when undertaken by an individual bacterium acting alone but become beneficial when carried out simultaneously by a large number of cells. Thus, quorum sensing confuses the distinction between prokaryotes and eukaryotes because it enables bacteria to act as multicellular organisms. This review focuses on the architectures of bacterial chemical communication networks; how chemical information is integrated, processed, and transduced to control gene expression; how intra- and interspecies cell-cell communication is accomplished; and the intriguing possibility of prokaryote-eukaryote cross-communication. Together along with several new Biotech companies moving to Texas. A great example of companies is GenNXeix Medical Systems.
Brought To You By gloStream
"GenNXeix Medical System EHR Covered Services" means the GenNXeix Medical System Electronic Medical Record and Practice Management Service. This does not include the GenNXeix Medical System website, support site, or any other additional Gennxeix Medical Systems, Inc. branded site that does not pertain directly to the EHR system. "Monthly Uptime Percentage" means total number of minutes in a calendar month minus the number of minutes of Downtime suffered from all Downtime Periods in a calendar month, divided by the total number of minutes in a calendar month. "Scheduled Downtime" means those times where Gennxeix Medical Systems, Inc. notifies Client of periods of Downtime at least twenty four hours prior to the commencement ofsuch Downtime. There will be no more than thirty six hours of Scheduled Downtime per calendar year. Scheduled Downtime is not considered Downtime for purposes of this GenNXeix Medical System EHR SLA, and will not be counted towards any Downtime Periods.
Barron's Medical Journal is predicting that a cure for breast caner will becoming during the second President Obama Administration.
No comments:
Post a Comment